Sunshine Coast Chapter Catchup

Mind Medicine Australia’s Sunshine Coast Chapter is pleased to invite you to an informal catch up at Sheelin Coates’ home in Noosa Heads.

There will be a light supper, drinks and a presentation by MMA’s founders Tania de Jong AM and Peter Hunt AM on Tuesday 27 July from 6-8pm.

This event will be an opportunity to connect with other chapter members and engage in the important discussion around mental health and emerging therapies.

Venue: 17 Banksia Ave, Noosa Heads QLD 4567, Australia
Date: Tuesday 27th of July 2021
Time: 6:00pm - 8pm

------------------------------------------------------------------

About Mind Medicine Australia

Mind Medicine Australia is Australia’s leading not-for-profit organisation working on the use of medicinal psilocybin and MDMA-assisted therapies to treat a range of mental illnesses. Mind Medicine Australia exists to help alleviate the suffering caused by our accelerating mental illness epidemic in Australia, through expanding the treatment options available to medical practitioners and their patients.

Unlike current treatments such as anti-depressants, which only manage the illness and can have undesirable side effects, psilocybin and MDMA assisted therapies have been scientifically proven to be a safe and effective cure for anxiety, depression, end-of-life stress, addictions and PTSD after just a short treatment program. These medicines are also currently being researched for dementia, eating disorders, OCD and a number of other conditions. Research from over 150 trials indicates that the medicines are safe and non-addictive when administered within a medically-controlled environment, and lead to remissions in 60-80% of patients after just 2-3 medicinal sessions in combination with psychotherapy.

Both medicines have been granted Breakthrough Therapy Status by the FDA in the USA to fast-track their approval. This designation is only given to medicines which may prove to be vastly superior to existing treatments.

------------------------------------------------------------------

About the Presenters

Peter Hunt AM
B.Com, LL.B
Founder & Chair of Mind Medicine Australia

As an investment banker Peter Hunt AM advised local and multi-national companies and governments in Australia for nearly 35 years. He co-founded and was Executive Chairman of one of Australia’s leading investment banking advisory firms, Caliburn Partnership (now called Greenhill Australia) and continued as Chairman of the Firm after its sale to Greenhill Inc in 2009. Peter is an active philanthropist involved in funding, developing and scaling social sector organisations which seek to create a better and fairer world. Peter was made a member of the General Division of the Order of Australia in the Queen’s Birthday Honours List in 2010 for services to the philanthropic sector.

Tania de Jong AM
LL.B (Hons), GradDipMus
Founder & Deputy Chair of Mind Medicine Australia

Tania de Jong AM is a trail-blazing Australian soprano, award-winning social entrepreneur, creative innovation catalyst, spiritual journey woman, storyteller and global speaker. Tania is one of Australia’s most successful female entrepreneurs and innovators developing 5 businesses and 3 charities over the past 3 decades. She is Founder and Executive Producer of future-shaping events series, Creative Innovation Global. She was appointed a Member of the Order of Australia in June 2008 and named one of the 100 Women of Influence and the 100 Australian Most Influential Entrepreneurs in 2018. is falling behind in the global psychedelic renaissance.

------------------------------------------------------------------

About Medicinal MDMA

Psychedelic-assisted therapies offer enormous potential in providing a meaningful alternative to current treatments for mental illness. PTSD is a debilitating condition that affects tens of millions of people worldwide, with many more trauma victims diagnosed with comorbid conditions such as depression, anxiety and eating disorders. In recent clinical trials, MDMA has been shown to produce reliable clinical improvements, restoring patient safety and self-agency even for individuals who have suffered with PTSD for many years, and for whom many treatments have failed.

Results from Phase 2 clinical trials over the past decade have been so compelling that the Food and Drug Administration (FDA) in the United States recently designated MDMA-assisted psychotherapy as a ‘Breakthrough Therapy’. This designation highlights the FDA’s anticipation that these therapies may offer substantial advantage over current treatments. If forthcoming Phase 3 results confirm these treatments are effective, MDMA-assisted treatment of PTSD may become a prescription medicine as early as 2021 in some jurisdictions.

The wave of clinical psychedelic research and regulatory support is rapidly building, with experts forecasting the availability of psychedelic-assisted treatments in the US and EU within the next 2 to 5 years, subject to positive clinical outcomes in large trials that are currently underway.

------------------------------------------------------------------

Many thanks to Mind Medicine Australia's Sunshine Coast Chapter for facilitating this event. Click here for more details or to join the Chapter!

Please support psychedelic research and therapy development by donating to Mind Medicine Australia. The recent pandemic has exacerbated Australia’s mental health epidemic and these treatments have the potential to cure millions of people who are suffering.

We are a small organisation doing big things – we need your support.

Please click here to make a tax-deductible donation.